News >

Multimodality Treatment Approach Necessary in Stage III NSCLC

Caroline Seymour
Published: Wednesday, Apr 24, 2019

David P. Mason, MD

David P. Mason, MD

Immunotherapy has reinvigorated the once stagnant space of unresectable stage III lung cancer, but for eligible patients, surgery remains a core aspect of care in this setting, said David P. Mason, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication